Which beta-blocker is commonly used in stable heart failure with reduced ejection fraction (HFrEF) and has proven mortality benefit?

Which beta-blocker is commonly used in stable heart failure with reduced ejection fraction (HFrEF) and has proven mortality benefit?

• A. Carvedilol
• B. Metoprolol Succinate
• C. Bisoprolol
• D. Propranolol

Answer: (A)

In stable heart failure with reduced ejection fraction, using a beta-blocker that has proven to improve survival is essential. Carvedilol fits this role well because it does more than just block beta receptors; it also blocks alpha-1 receptors. That dual action leads to vasodilation and lower afterload, which reduces the heart’s workload and helps improve cardiac function over time. This combination has shown a clear mortality benefit in major trials, making carvedilol a commonly chosen option in long-term management of HFrEF. While other beta-blockers like metoprolol succinate and bisoprolol also improve outcomes in HFrEF, carvedilol’s vasodilatory effect adds a distinct advantage in many patients, especially those with higher vascular resistance. Propranolol, on the other hand, is not associated with proven mortality benefit in stable HFrEF and is not routinely used for this purpose.

In stable heart failure with reduced ejection fraction, using a beta-blocker that has proven to improve survival is essential. Carvedilol fits this role well because it does more than just block beta receptors; it also blocks alpha-1 receptors. That dual action leads to vasodilation and lower afterload, which reduces the heart’s workload and helps improve cardiac function over time. This combination has shown a clear mortality benefit in major trials, making carvedilol a commonly chosen option in long-term management of HFrEF.

While other beta-blockers like metoprolol succinate and bisoprolol also improve outcomes in HFrEF, carvedilol’s vasodilatory effect adds a distinct advantage in many patients, especially those with higher vascular resistance. Propranolol, on the other hand, is not associated with proven mortality benefit in stable HFrEF and is not routinely used for this purpose.